Regulatory Updates

Latest News

FDA Grants Full Approval to Rybrevant in Lung Cancer
FDA Grants Full Approval to Rybrevant in Lung Cancer

March 1st 2024

Rybrevant is indicated to be used in combination with chemotherapy as a first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer.

teguhjatipras-stock.adobe.com
FDA Sets Action Date for Axatilimab in Graft-Versus-Host Disease

February 28th 2024

PIC4U-stock.adobe.com
FDA Sets Review Date for Tislelizumab in Stomach Cancer

February 28th 2024

FDA Grants Priority Review for Second Epkinly Indication
FDA Grants Priority Review for Second Epkinly Indication

February 27th 2024

FDA Expands Indication for Biktarvy for Those with Resistant HIV
FDA Expands Indication for Biktarvy for Those with Resistant HIV

February 27th 2024

Latest CME Events & Activities

More News

© 2024 MJH Life Sciences

All rights reserved.